Impact of Mifepristone, a Glucocorticoid/Progesterone Antagonist, on HDL Cholesterol, HDL Particle Concentration, and HDL Function | Zendy

Stephanie T. Page | Zendy; Ronald M. Krauss | Zendy; Coleman Gross | Zendy; Brian Y. Ishida | Zendy; Jay W. Heinecke | Zendy; Chongren Tang | Zendy; John K. Amory | Zendy; Peter M. Schaefer | Zendy; Cheryl J. Cox | Zendy; John P. Kane | Zendy; Jonathan Q. Purnell | Zendy; Richard L. Weinstein | Zendy; Tomáš Vaisar | Zendy

Open Access

Impact of Mifepristone, a Glucocorticoid/Progesterone Antagonist, on HDL Cholesterol, HDL Particle Concentration, and HDL Function

Author(s) -

Stephanie T. Page,

Ronald M. Krauss,

Coleman Gross,

Brian Y. Ishida,

Jay W. Heinecke,

Chongren Tang,

John K. Amory,

Peter M. Schaefer,

Cheryl J. Cox,

John P. Kane,

Jonathan Q. Purnell,

Richard L. Weinstein,

Tomáš Vaisar

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2813

Subject(s) - mifepristone , medicine , endocrinology , cholesterol , placebo , antiglucocorticoid , high density lipoprotein , cholesterylester transfer protein , glucocorticoid , progestin , lipoprotein , biology , glucocorticoid receptor , estrogen , pregnancy , genetics , alternative medicine , pathology

Mifepristone is a glucocorticoid and progestin antagonist under investigation for the treatment of Cushing's syndrome. Mifepristone decreases high-density lipoprotein (HDL) cholesterol (HDL-C) levels in treated patients, but the clinical significance of this is unclear because recent studies suggest that functional properties of HDL predict cardiovascular disease status better than does HDL-C concentration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research